Angelo RavelliShow email address
Dipartimento di Neuroscienze, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, ITALY | Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Dipartimento di ...
Is this your profile? Claim your profile Copy URL Embed Link to your profile
Angelo Ravelli:Expert Impact
Concepts for whichAngelo Ravellihas direct influence:Juvenile idiopathic arthritis,Macrophage activation syndrome,Inactive disease,Idiopathic arthritis,Juvenile dermatomyositis,Juvenile idiopathic,Radiographic progression,Clinical remission.
Angelo Ravelli:KOL impact
Concepts related to the work of other authors for whichfor which Angelo Ravelli has influence:Juvenile idiopathic arthritis,Macrophage activation syndrome,Systemic lupus erythematosus,Rheumatic diseases,Patients jia,Kawasaki disease.
KOL Resume for Angelo Ravelli
Dipartimento di Neuroscienze, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, ITALY
Direzione Scientifica, Istituto Giannina Gaslini Istituto Pediatrico di Ricovero e Cura a Carattere Scientifico, Genova, Italy
RITA, European Reference Networks, Brussels, Belgium
Sechenov First Moscow State Medical University, Moscow, Russian Federation
Department of Pediatric Rheumatology, Sechenov First Moscow State Medical University, Moscow, Russian
Università degli Studi di Genova, Dipartimento di Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno‐Infantili, Genova, Italy
Clinic of Pediatrics and Rheumatology, IRCCS G. Gaslini and University of Genoa.
Department of Paediatric Rheumatology, Gaslini Children's Hospital, Genoa, Italy
IRCCS Istituto Giannina Gaslini - Paediatric Rheumatology International Trials Organisation (PRINTO)
Gaslini Children’s Hospital, Genoa, Italy
A. Martini, MD, Professor, IRCCS Istituto Giannina Gaslini, Direzione Scientifica; A. Ravelli, MD, Professor, IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia and Università degli Studi di Genova; T. Avcin, MD, PhD, University Children's Hospital, University Medical Center Ljubljana, Department of Allergology, Rheumatology and Clinical Immunology; M.W. Beresford, MBChB, PhD, Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, and Institute of Translational Medicine, University of Liverpool; R. Burgos-Vargas, MD, Hospital General de Mexico, Departamento de Reumatología; R. Cuttica, MD, Hospital Pedro de Elizalde, Rheumatology Section; N.T. Ilowite, MD, Children's Hospital at Montefiore, Albert Einstein College of Medicine, Pediatrics; R. Khubchandani, MD, Jaslok Hospital and Research Centre, Department of Paediatrics; R.M. Laxer, MD, The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto; D.J. Lovell, MD, MPH, Cincinnati Children's Hospital Medical Center, Division of Rheumatology; R.E. Petty, MD, PhD, British Columbia Children's Hospital, Department of Pediatrics, University of British Columbia; C.A. Wallace, MD, Seattle Children's Hospital; N.M. Wulffraat, MD, PhD, Wilhelmina Children's Hospital, Department of Pediatric Immunology and Rheumatology; A. Pistorio, MD, PhD, IRCCS Istituto Giannina Gaslini, Servizio di Epidemiologia e Biostatistica; N. Ruperto, MD, MPH, IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, PRINTO.
From Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Direzione Scientifica; IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Pediatric Rheumatology International Trials Organization (PRINTO), and Università degli Studi di Genova; IRCCS Istituto Giannina Gaslini, Servizio di Epidemiologia e Biostatistica, Genoa, Italy; University Children's Hospital, University Medical Center Ljubljana, Department of Allergology, Rheumatology and Clinical Immunology, Ljubljana, Slovenia; Department of Paediatric Rheumatology, Alder Hey Children's National Health Service (NHS) Foundation Trust; Institute of Translational Medicine, University of Liverpool, Liverpool, UK; Hospital General de Mexico, Departamento de Reumatología, Mexico City, Mexico; Hospital Pedro de Elizalde, Rheumatology Section, Buenos Aires, Argentina; Children's Hospital at Montefiore, Albert Einstein College of Medicine, Pediatrics, New Hyde Park, New York; Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, Ohio; Seattle Children's Hospital, Seattle, Washington, USA; Jaslok Hospital and Research Centre, Department of Paediatrics, Mumbai, India; The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, Ontario; British Columbia Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada; Wilhelmina Children's Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, the Netherlands.
Istituto G. Gaslini, Pediatria II-Reumatologia, Genova, Italy.
Dipartimento di Pediatria, Università di Genova, Genoa, Italy
Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Pediatric Rheumatology and Pediatric Health Services Research, University of Michigan CS Mott Children's Hospital, Ann Arbor, Michigan; Office of Research, Division of Rheumatology, Columbia University Medical Center, New York; Division of Rheumatology, University of Rochester, Golisano Children's Hospital, Rochester, New York; Thornhill Associates, Hermosa Beach; Division of Immunology/Rheumatology, Stanford University, Stanford, California; Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Arthritis Foundation, Atlanta, Georgia; Division of Rheumatology, Children's Mercy, Kansas City, Missouri; Division of Pediatric Rheumatology, Rutgers Robert Wood Johnson Medical School, Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey; Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Rheumatology, Seattle Children's Hospital, Seattle, Washington; Johns Hopkins Arthritis Center, Johns Hopkins University, Baltimore, Maryland, USA; Division of Rheumatology, Istituto Giannina Gaslini; University of Genoa, Genoa, Italy; Rheumatology, Royal Children's Hospital; Murdoch Children's Research Institute, Melbourne, Australia; The Hospital for Sick Children, and Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto; Children's Hospital of Eastern Ontario Research Institute, Department of Pediatrics and School of Rehabilitation Sciences, University of Ottawa, Ottawa, Ontario, Canada.
University of Genova, Genoa, Italy
|canakinumab historical cohort||#1|
|adult rheumatology patients||#1|
|patient symptoms children||#1|
|vaccinations paediatric patients||#1|
|polyarthritis crosssectional visit||#1|
|systemic arthritis score||#1|
|active sjia levels||#1|
|preschool consensus databases||#1|
|biologic medications jia||#1|
|jiaassociated uveitis recommendations||#1|
|ferritin sjia patients||#1|
|patients biologic cohort||#1|
|active joints presence||#1|
|2016 classification criteria||#1|
|20 sojia patients||#1|
|ifnγ induced chemokines||#1|
|age disease presentation||#1|
|damage functional disability||#1|
|jadas10 cutoffs oligoarthritis||#1|
|thrombocytopenia higher levels||#1|
|synovitis flare patients||#1|
|histologic clinical features||#1|
|15 ≥ 15||#1|
|canakinumab lower ferritin||#1|
|Sign-in to see all concepts, it's free!|
Prominent publications by Angelo Ravelli
OBJECTIVE: To characterize disease activity patterns in a large cohort of children with juvenile idiopathic arthritis (JIA), by applying newly developed preliminary definitions of inactive disease, clinical remission on medication, and clinical remission off medication.
METHODS: Children with persistent or extended oligoarthritis, polyarthritis (either rheumatoid factor [RF] positive or RF negative), or systemic JIA who had been followed up for a period of at least 4 years were evaluated ...
|Known for Clinical Remission | Inactive Disease | Select Categories | 5 Years | Juvenile Idiopathic|
The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the disease activity
[ PUBLICATION ]
OBJECTIVE: To validate and promulgate a core set of outcome measures for the evaluation of response to treatment in patients with juvenile systemic lupus erythematosus (SLE).
METHODS: In 2001, a preliminary consensus-derived core set of measures for evaluating the response to therapy in juvenile SLE was established. In the present study, the core set was validated through an evidence-based, large-scale data collection process that led to the enrollment of 557 patients from 39 different ...
|Known for Response Therapy | Lupus Erythematosus | Prospective Validation | Juvenile Systemic | International Trials|
Level of agreement between children, parents, and physicians in rating pain intensity in juvenile idiopathic arthritis
[ PUBLICATION ]
OBJECTIVE: To investigate the level of agreement between patients, mothers, fathers, and physicians in rating pain intensity in juvenile idiopathic arthritis (JIA), and to identify factors explaining discrepancies between raters.
METHODS: Ninety-four children with JIA and their mothers and fathers were asked to rate independently the intensity of present pain and pain in the previous week on a visual analog scale. The physicians rated pain intensity after physical examination. Agreement ...
|Known for Pain Children | Juvenile Idiopathic Arthritis | Mothers Fathers | Level Agreement | Parents Physicians|
The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: P
[ PUBLICATION ]
OBJECTIVE: To use the Pediatric Rheumatology International Trials Organization (PRINTO) core set of outcome measures to develop a validated definition of improvement for the evaluation of response to therapy in juvenile systemic lupus erythematosus (SLE).
METHODS: Thirty-seven experienced pediatric rheumatologists from 27 countries, each of whom had specific experience in the assessment of juvenile SLE patients, achieved consensus on 128 patient profiles as being clinically improved or ...
|Known for Lupus Erythematosus | Provisional Criteria | Juvenile Systemic | Rheumatology International | Prospective Validation|
European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative
[ PUBLICATION ]
Childhood-onset systemic lupus erythematosus (cSLE) is a rare, multisystem and potentially life-threatening autoimmune disorder with significant associated morbidity. Evidence-based guidelines are sparse and management is often based on clinical expertise. SHARE (Single Hub and Access point for paediatric Rheumatology in Europe) was launched to optimise and disseminate management regimens for children and young adults with rheumatic diseases like cSLE. Here, we provide evidence-based ...
|Known for Based Recommendations | Lupus Erythematosus | Onset Systemic | Share Initiative | European Evidence|
Methotrexate Withdrawal at 6 vs 12 Months in Juvenile Idiopathic Arthritis in Remission: A Randomized Clinical Trial
[ PUBLICATION ]
CONTEXT: Novel therapies have improved the remission rate in chronic inflammatory disorders including juvenile idiopathic arthritis (JIA). Therefore, strategies of tapering therapy and reliable parameters for detecting subclinical inflammation have now become challenging questions.
OBJECTIVES: To analyze whether longer methotrexate treatment during remission of JIA prevents flares after withdrawal of medication and whether specific biomarkers identify patients at risk for flares.
|Known for 12 Months | Methotrexate Withdrawal | Patients Jia | Juvenile Idiopathic Arthritis | Clinical Trial|
BACKGROUND: In 2012, a European initiative called Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases. Juvenile dermatomyositis (JDM) is a rare disease within the group of paediatric rheumatic diseases (PRDs) and can lead to significant morbidity. Evidence-based guidelines are sparse and management is mostly based on physicians' ...
|Known for Based Recommendations | Juvenile Dermatomyositis | Treatment Jdm | 80 Agreement | Rheumatic Diseases|
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial
[ PUBLICATION ]
BACKGROUND: Most data for treatment of dermatomyositis and juvenile dermatomyositis are from anecdotal, non-randomised case series. We aimed to compare, in a randomised trial, the efficacy and safety of prednisone alone with that of prednisone plus either methotrexate or ciclosporin in children with new-onset juvenile dermatomyositis.
METHODS: We did a randomised trial at 54 centres in 22 countries. We enrolled patients aged 18 years or younger with new-onset juvenile dermatomyositis who ...
|Known for Juvenile Dermatomyositis | Prednisone Methotrexate | Clinical Remission | Agents Child | New Onset|
BACKGROUND: Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA; treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA.
METHODS: We randomly assigned 112 children, 2 to 17 years of age, with active systemic JIA (duration of ≥6 months and inadequate responses to nonsteroidal antiinflammatory drugs and glucocorticoids) to the anti-interleukin-6 receptor antibody tocilizumab (at a dose of 8 mg per kilogram of body weight if the ...
|Known for Patients Tocilizumab | Humanized Arthritis | Nonsteroidal Antibodies | Systemic Juvenile | Pathogenic Role|
[ PUBLICATION ]
OBJECTIVE: To identify a core set of outcome variables for the assessment of children with juvenile arthritis (JA), to use the core set to develop a definition of improvement to determine whether individual patients demonstrate clinically important improvement, and to promote this definition as a single efficacy measure in JA clinical trials.
METHODS: A core set of outcome variables was established using a combination of statistical and consensus formation techniques. Variables in the ...
|Known for Definition Improvement | Juvenile Arthritis | Core Outcome Variables | Sensitivity Specificity | Limited Range|
Proxy‐reported health‐related quality of life of patients with juvenile idiopathic arthritis: The pediatric rheumatology international trials organization multinational quality of life cohort study
[ PUBLICATION ]
OBJECTIVE: To investigate the proxy-reported health-related quality of life (HRQOL) and its determinants in patients with juvenile idiopathic arthritis (JIA).
METHODS: In this multinational, multicenter, cross-sectional study, HRQOL of patients with JIA was assessed through the Child Health Questionnaire (CHQ) and was compared with that of healthy children of similar age from the same geographic area. Potential determinants of HRQOL included demographic data, physician's and parent's ...
|Known for Hrqol Patients | Life Cohort Study | Idiopathic Arthritis | Healthy Children | Chq Jia|
A randomized, placebo‐controlled trial of infliximab plus methotrexate for the treatment of polyarticular‐course juvenile rheumatoid arthritis
[ PUBLICATION ]
OBJECTIVE: To evaluate the safety and efficacy of infliximab in the treatment of juvenile rheumatoid arthritis (JRA).
METHODS: This was an international, multicenter, randomized, placebo-controlled, double-blind study. One hundred twenty-two children with persistent polyarticular JRA despite prior methotrexate (MTX) therapy were randomized to receive infliximab or placebo for 14 weeks, after which all children received infliximab through week 44. Patients received MTX plus infliximab 3 ...
|Known for Patients Infliximab | Juvenile Rheumatoid Arthritis | Mtx Placebo | Acr Pedi | 6 Week|
Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
[ PUBLICATION ]
OBJECTIVES: Interferon-γ (IFNγ) is the pivotal mediator in murine models of primary haemophagocytic lymphohistiocytosis (pHLH). Given the similarities between primary and secondary HLH (sec-HLH), including macrophage activation syndrome (MAS), we investigate the involvement of the IFNγ pathway in MAS by evaluating levels of IFNγ and of the induced chemokines, and their relation with laboratory parameters of MAS in systemic juvenile idiopathic arthritis (sJIA) patients with MAS and in a ...
|Known for Macrophage Activation | Levels Ifnγ | Patients Active Sjia | Systemic Juvenile | Idiopathic Arthritis|